Literature DB >> 32047890

Ruxolitinib can cause weight gain by blocking leptin signaling in the brain via JAK2/STAT3.

Nicole Mollé1,2, Spencer Krichevsky2, Pouneh Kermani1, Richard T Silver1,2, Ellen Ritchie1,2, Joseph M Scandura1,2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32047890     DOI: 10.1182/blood.2019003050

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  5 in total

1.  Ruxolitinib Controls Lymphoproliferation and Diabetes in a STAT3-GOF Patient.

Authors:  Oliver Wegehaupt; Tina Muckenhaupt; Matthew B Johnson; Karl Otfried Schwab; Carsten Speckmann
Journal:  J Clin Immunol       Date:  2020-09-17       Impact factor: 8.317

Review 2.  Metabolic Vulnerabilities and Epigenetic Dysregulation in Myeloproliferative Neoplasms.

Authors:  Vasundhara Sharma; Kenneth L Wright; Pearlie K Epling-Burnette; Gary W Reuther
Journal:  Front Immunol       Date:  2020-11-30       Impact factor: 7.561

3.  Leptin Promotes Angiogenesis via Pericyte STAT3 Pathway upon Intracerebral Hemorrhage.

Authors:  Qi Cui; Yingmei Zhang; Ning Tian; Jiaxin Yang; Dongshan Ya; Wenjing Xiang; Zixian Zhou; Yanlin Jiang; Jungang Deng; Bin Yang; Xiaohui Lin; Qinghua Li; Rujia Liao
Journal:  Cells       Date:  2022-09-03       Impact factor: 7.666

Review 4.  Haematological Drugs Affecting Lipid Metabolism and Vascular Health.

Authors:  Antonio Parrella; Arcangelo Iannuzzi; Mario Annunziata; Giuseppe Covetti; Raimondo Cavallaro; Emilio Aliberti; Elena Tortori; Gabriella Iannuzzo
Journal:  Biomedicines       Date:  2022-08-10

Review 5.  Emerging Place of JAK Inhibitors in the Treatment of Inborn Errors of Immunity.

Authors:  Jérôme Hadjadj; Marie-Louise Frémond; Bénédicte Neven
Journal:  Front Immunol       Date:  2021-09-17       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.